Abstract:Purpose: The rational discovery and development of new antiepileptic drugs (AEDs) with safer therapeutic index and better pharmacokinetic properties is still warranted nowadays. Because the long-term management of epilepsy is attained by means of orally administered AEDs, investigation of their potential to be well absorbed at the intestinal level is mandatory. Moreover, involvement of the efflux transport mediated by P-glycoprotein (P-gp) may compromise the systemic and central nervous system disposition of AEDs. Therefore, this study aimed at characterizing mouse jejunal passive transport and the possible active efflux mediated by P-gp of a series of dibenz[b,f]azepine-5-carboxamide derivatives (carbamazepine [CBZ], oxcarbazepine [OXC], S-licarbazepine [S-Lic], R-licarbazepine [R-Lic], carbamazepine-10,11-epoxide [CBZ-E], 10,11-trans-dihydroxy-10,11-dihydro-carbamazepine [trans-diol], and BIA 2-024), which comprise some AEDs and metabolites. Methods: Permeation studies were performed with freshly excised mouse jejunum segments mounted in Ussing chambers. Absorptive (M-S) and secretive (S-M) transports were analyzed with and without verapamil, which is a P-gp inhibitor widely recognized. Apparent permeability coefficients (P(app) ) in both directions and in absence or presence of verapamil were determined for each test compound. The in vitro method was validated using five controls that included high and low permeable markers with known absorption fraction (Fa) and also well-known P-gp substrates. The integrity of intestinal membrane was guaranteed during the assay by measuring the transepithelial electrical resistance. Key findings: The correlation obtained between P(app) (M-S) and Fa of references was high (r(2) = 0.9945), and could be used to classify the derivatives according to Biopharmaceutical Classification System: CBZ and OXC were the only classified as highly permeable. The P(app) (S-M) of OXC, CBZ-E, R-Lic, and BIA 2-024 were significantly higher than their P(app) (M-S). After verapamil addition, their P(app) (S-M) lowered while P(app) (S-M) increased, suggesting the involvement of P-gp on the transport of those compounds across mouse jejunum segments. In opposition, CBZ, S-Lic, and trans-diol presented no statistical differences between the P(app) values reported in both directions, with or without verapamil. The results reported herein suggest that differences in biodisposition of S-Lic and R-Lic might result from their distinct interaction with P-gp. Significance: The Ussing chamber model used herein showed to be useful for predicting Fa of AEDs and the involvement of efflux transport, namely P-gp, on their absorption. This is an important achievement as compounds that are not transported by P-gp may offer advantages when used in patients with pharmacoresistant epilepsy.

Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers

Pharmacokinetics of the Monohydroxy Derivative of Oxcarbazepine and Its Enantiomers after a Single Intravenous Dose Given as Racemate Compared with a Single Oral Dose of Oxcarbazepine

Evaluation of the Effects of Ketoconazole and Voriconazole on the Pharmacokinetics of Oxcarbazepine and Its Main Metabolite MHD in Rats by UPLC-MS-MS.

Influence of verapamil on the pharmacokinetics of oridonin in rats

Influence of Verapamil on Pharmacokinetics of Triptolide in Rats

Saliva And Plasma Monohydroxycarbamazepine Concentrations In Pediatric Patients With Epilepsy

Population pharmacokinetics of oxcarbazepine 10-monohydroxy derivative in Chinese adult epileptic patients

Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug‐Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open‐Label Studies in Healthy Subjects

Relationship Between Cytochromes P450 2C19 * 2 Genotype and the Concentration of the Active Oxcarbazepine Metabolite in Pediatric Patients with Epilepsy

Determination of Active Metabolite of Oxcarbazepine by RP-HPLC and Study of Its Pharmacokinetics in Chinese Healthy Volunteers

Effect of verapamil on electrobiological activity and seizure behavior in phenytoin-carbamazepine resistant rats

Analysis of the Influencing Factors of the Plasma Concentration of Oxcarbazepine Active Metabolite in Children with Epilepsy

Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children

Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique

Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection

Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy

Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy

Comparative Pharmacokinetics of Verapamil and Norverapamil in Normal and Ulcerative Colitis Rats after Oral Administration of Low and High Dose Verapamil by UPLC-MS/MS.

Serum concentration analysis of oxcarbazepine active metabolite in children with epilepsy

Effects of UGT1A9 Genetic Polymorphisms on Monohydroxylated Derivative of Oxcarbazepine Concentrations and Oxcarbazepine Monotherapeutic Efficacy in Chinese Patients with Epilepsy

Effects of ABCB1, ABCC2, UGT2B7 and HNF4α Genetic Polymorphisms on Oxcarbazepine Concentrations and Therapeutic Efficacy in Patients with Epilepsy.